期刊论文

Multi-centrally Clinical Trial of Fuzhenghuayu (Strengthening Healthy Qi to Solve Stagnation) Capsules on Liver Filbrosis Caused by Chronic Hepatitis B

中文

世界科学技术-中医药现代化

1674-3849

2005

7

1

24-32

10.3969/j.issn.1674-3849.2005.01.006

上海市医学发展基金重点研究项目（No:99ZD1001）:复方319胶囊干预肝纤维化的研究；

本校为其他机构

目的:观察扶正化瘀胶囊治疗慢性乙型肝炎肝纤维化的临床疗效及安全性.方法:多中心、随机、双盲、平行对照,对照药为和络舒肝胶囊,疗程24周并随访12周.结果:试验组110例,对照组106例,其中治疗前进行肝组织学检查者分别为99例和96例,治疗后作2次肝活检者分别为50例和43例.治疗后,试验组纤维化分期降低1期以上者占52%,显著高于对照组(23.3%),同时肝组织炎症活动度显著下降;试验组治疗12周、24周时的血清HA、LN、P-Ⅲ-P及Ⅳ-C含量较治疗前均显著下降,其差值均显著大于对照组;两组血清Alb、ALT、AST、GGT、ALP均有显著改善;但试验组血清ALT改善率、GGT的下降值及Alb含量的增加值均显著大于对照组.未发...

Objective: To observe the efficacy and safety of Fuzhenghuayu (strengthening healthy Qi to solve stagnation) Capsules in liver fibrosis caused by chronic hepatitis B. Method: Trials of multi - center, randomization, double blindness and parallel control (with Heluoshugan Capsules as control medicine) are conducted in patients suffering from liver fibrosis caused by Chronic hepatitis B in 24 weeks and followed by 12 -week visit. Result: 110 cases of the experimental group and 106 cases of the control group have been placed into the trial, among ...